References
- Diagnosis and management of preeclampsia and eclampsia. ACOG Practice Bulletin No. 33. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002;99:159–67
- Benigni A, Gregorini G, Frusca T, et al. Effect of low-dose aspirin on fetal and maternal generation of thromboxane by platelets in women at risk for pregnancy-induced hypertension. N Engl J Med 1989;321:357–62
- Hauth JC, Goldenberg RL, Parker CR Jr, et al. Low-dose aspirin therapy to prevent preeclampsia. Am J Obstet Gynecol 1993;168:1083–91
- Schiff E, Peleg E, Goldenberg M, et al. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high risk pregnancies. NEJM 1989;321:351–6
- Beaufils M, Uzan S, Donsimoni R, Colau JC. Prevention of pre-eclampsia by early antiplatelet therapy. Lancet 1985;325:840–2
- Caritis S, Sibai B, Hauth J, et al. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1998;338:701–5
- CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet 1994;343:619–29
- Sibai BM, Caritis SN, Thom E, et al. Prevention of preeclampsia with low-dose aspirin in healthy, nulliparous pregnant women. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 1993;329:1213–8
- Duley L, Henderson-Smart D, Knight M, King J. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2007;2:CD004659
- Askie L, Duley L, Henderson-Smart D, Stewart L. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet 2007;369:1791–8
- Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet Gynecol 2010;116:402–14
- Roberts J, Bodnar L, Patrick T, Powers R. The role of obesity in preeclampsia. Pregnancy Hypertens 2011;1:6–16
- Yu C, Teoh T, Robinson S. Obesity in pregnancy. BJOG 2006;113:1117–25
- Bodnar LM, Catov JM, Klebanoff MA, et al. Prepregnancy body mass index and the occurrence of severe hypertensive disorders of pregnancy. Epidemiology 2007;18:234–9
- Brill M, Diepstraten J, Rongen A, et al. Impact on drug metabolism and elimination in adults and children. Clin Pharm 2012;51:277–304
- Lexi-Comp Online™. Hudson (OH): Lexi-Comp, Inc. Available from: www.lexi.com/ [last accessed 4 June 2014]
- Ebrashy A, Ibrahim M, Marzook A, et al. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14–16 weeks pregnancy: a randomized controlled clinical trial. Croat Med J 2005;46:826–31
- Roberge S, Villa P, Nicolaides K, et al. Early administration of low-dose aspirin for the prevention of preterm and term preeclampsia: a systematic review and meta-analysis. Fetal Diagn Ther 2012;31:141–6
- Roberge S, Giguere Y, Villa P, et al. Early administration of low-dose aspirin for the prevention of severe and mild preeclampsia: a systematic review and meta-analysis. Am J Perinatol 2012;29:551–6
- O'Brien T, Ray J, Chan W. Maternal body mass index and the risk of preeclampsia: a systematic overview. Epidemiology 2003;14:368–74
- Wolf M, Kettyle E, Sandler L, et al. Obesity and preeclampsia: the potential role of inflammation. Obstet Gynecol 2001;98:757–62
- Roberts J, Catov J. Aspirin for pre-eclampsia: compelling data on benefit and risk. Lancet 2007;369:1765–6